Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Zhang, Yanli  [Clear All Filters]
Journal Article
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.
Luo H, Liu W, Zhou Y, Zhang Y, Wu J, Wang R, Shao L. Stage-specific requirement for METTL3-dependent mA modification during dental pulp stem cell differentiation. J Transl Med. 2022;20(1):605.
Huang Z, Li Z, Wang J, Gui R, Zu Y, Yu F, Lin Q, Zhao H, Zhang Y, Fang B, et al. A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy. Front Oncol. 2023;13:1162413.
Sheng L, Li T, Li Y, Zhou M, Wang J, Lai Y, Zhang Y, Yi P, Mu Q, Ouyang G. Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features. Heliyon. 2023;9(9):e19342.
Lai B, Mu Q, Zhang Y, Chen Y, Yan X, Ouyang G. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen. Hematology. 2021;26(1):751-757.
Cai Y, Liu Z, Zhang G, Yang Y, Zhang Y, Wang F, Deng M. miR-101-5p overexpression suppresses the proliferation of goat spermatogonial stem cells by targeting EZH2. Anim Reprod Sci. 2023;255:107281.
Wang P, Zhang Y, Lv X, Zhou J, Cang S, Song Y. LncRNA ADAMTS9-AS1 inhibits the stemness of lung adenocarcinoma cells by regulating miR-5009-3p/NPNT axis. Genomics. 2023:110596.
Pang J, Yang H, Feng X, Wang Q, Cai Y, Liu Z, Wang C, Wang F, Zhang Y. HT-2 toxin affects cell viability of goat spermatogonial stem cells through AMPK-ULK1 autophagy pathways. Theriogenology. 2021;164:22-30.
Cai Y, Deng M, Liu Z, Zhang G, Pang J, An S, Wang Z, Zhang Y, Wang F. EZH2 expression and its role in spermatogonial stem cell self-renewal in goats. Theriogenology. 2020;155:222-231.
Xie N, Zhou J, Zhang Y, Yu F, Song Y. Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective study. Medicine (Baltimore). 2019;98(19):e15584.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
Gui RR, Li Z, Zu YL, Wang J, Liu YY, Zhang BL, Yu FK, Zhang Y, Zhao HF, Wang P, et al. [CMV-CTL for treatment of refractory CMV infection in 17 patients following alternative donor hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(10):865-868.
Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021.